BibbInstruments

BibbInstruments FCF/Net Income

The Free Cash Flow to Net Income Ratio of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is 123.72 %. In the previous year, Free Cash Flow to Net Income Ratio was 143.66 % — a change of -13.88% (lower).

FCF/Net Income

123.72 %

YoY

-13.88%

Last updated:

Free Cash Flow to Net Income Ratio of BibbInstruments is 2025 123.72 % . Free Cash Flow to Net Income Ratio of BibbInstruments was 2024 143.66 % . It decreases by -13.88% lower compared to the previous year.

The BibbInstruments FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
158.23 SEK
Jan 1, 2019
121.76 SEK
Jan 1, 2020
106.21 SEK
Jan 1, 2021
145.37 SEK
Jan 1, 2022
133.31 SEK
Jan 1, 2023
137.73 SEK
Jan 1, 2024
143.66 SEK
Jan 1, 2025
123.72 SEK
The BibbInstruments FCF/Net Income history
YEARFCF/Net IncomeYoY
123.72 %-13.88%
143.66 %+4.30%
137.73 %+3.32%
133.31 %-8.30%
145.37 %+36.86%
106.21 %-12.77%
121.76 %-23.05%
158.23 %+21.73%
129.99 %-100.18%
-71,285.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BibbInstruments AB is a specialized medical technology enterprise headquartered in Lund, Sweden, operating within the health care sector. The company focuses on the development and marketing of advanced diagnostic instruments designed for the early detection of cancerous tumors. BibbInstruments went public on the Stockholm Stock Exchange on October 27, 2017, under the ticker symbol BIBB.SL, with the associated ISIN SE0010102095. Despite its technological focus, the organization maintains a lean operational structure, currently employing only four full-time staff members. The core of the company’s innovation lies in its proprietary technology platform known as EndoDrill. This platform utilizes a unique drill function that facilitates early cancer diagnosis, particularly within deep skin tissues and internal organs, offering a minimally invasive alternative to traditional biopsy methods. The product portfolio is diverse and tailored to specific medical needs across various bodily systems. It includes the EndoDrill GI Upper, which is engineered for stomach biopsies, and the EndoDrill GI Lower, designed for intestinal procedures. For respiratory diagnostics, the company offers the EndoDrill GI Lung for lung biopsies. Beyond diagnosis, the portfolio extends into therapeutic applications through the EndoDrill Therapy device, which allows for the passage of displacements in different organs to facilitate the placement of conductors, balloons, and stents for treatment purposes. Additionally, the EndoDrill Needle is available for breast biopsies, while the EndoDrill Model X serves multiple areas and is currently part of an independent research project. The company’s distribution strategy is primarily concentrated on Scandinavian countries, targeting hospitals equipped with endoscopy specialist centers and surgical wards. By focusing on these specific clinical environments, BibbInstruments aims to provide healthcare professionals with precise tools that enhance diagnostic accuracy and patient outcomes. The company’s website, https://www.bibbinstruments.com/, serves as the primary digital hub for information regarding its products and technological advancements. As a small but focused entity, BibbInstruments AB represents a niche player in the global medical device market, emphasizing innovation in early cancer detection through its specialized EndoDrill technology. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Free Cash Flow to Net Income Ratio of BibbInstruments is 123.72 % in 2025.

Free Cash Flow to Net Income Ratio of BibbInstruments changed from 143.66 % to 123.72 %, representing a -13.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's BibbInstruments with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BibbInstruments

All Key Metrics — BibbInstruments